CurrentRheuma
Get Weekly

CurrentRheuma coverage · page 15 of 15

Annals of the Rheumatic Diseases

Briefs 561–596 of 596 CurrentRheuma has covered from this journal, newest publication first

Latest from Annals of the Rheumatic Diseases

All coverage, newest first

  1. Ann Rheum Dis

    Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial

    Randomized controlled trialRA

  2. Ann Rheum Dis

    Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis

    Randomized controlled trialRA

  3. Ann Rheum Dis

    Impact of vaccination on postacute sequelae of SARS CoV-2 infection in patients with rheumatic diseases

    Cohort studyAcross diseases

  4. Ann Rheum Dis

    Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

    Research articleRA

  5. Ann Rheum Dis

    Genome-wide association meta-analysis of knee and hip osteoarthritis uncovers genetic differences between patients treated with joint replacement and patients without joint replacement

    Meta-analysisOsteoarthritis

  6. Ann Rheum Dis

    Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

    Cohort studyRA

  7. Ann Rheum Dis

    Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

    Research articleRA

  8. Ann Rheum Dis

    EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

    Guideline or statementRA

  9. Ann Rheum Dis

    2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases

    Guideline or statementAcross diseases

  10. Ann Rheum Dis

    American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision

    Diagnostic or prognostic studyRA

  11. Ann Rheum Dis

    Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis

    Cohort studySpondyloarthritis & PsA

  12. Ann Rheum Dis

    ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

    Guideline or statementSpondyloarthritis & PsA

  13. Ann Rheum Dis

    Tenderness and radiographic progression in rheumatoid arthritis and psoriatic arthritis

    Cohort studyRA

  14. Ann Rheum Dis

    Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

    Research articleSpondyloarthritis & PsA

  15. Ann Rheum Dis

    Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study

    Meta-analysisLupus & APS

  16. Ann Rheum Dis

    Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis

    Mechanistic studySystemic sclerosis

  17. Ann Rheum Dis

    Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports

    Cohort studyLupus & APS

  18. Ann Rheum Dis

    Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

    Cohort studyRA

  19. Ann Rheum Dis

    Low copy numbers of complement C4 and C4A deficiency are risk factors for myositis, its subgroups and autoantibodies

    Case-control studyMyositis

  20. Ann Rheum Dis

    Deciphering the role of cDC2s in Sjögren's syndrome: transcriptomic profile links altered antigen processes with IFN signature and autoimmunity

    Mechanistic studySjögren's & overlap

  21. Ann Rheum Dis

    Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis

    Cohort studyRA

  22. Ann Rheum Dis

    Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

    Secondary analysisRA

  23. Ann Rheum Dis

    Understanding sex-related differences in healthcare utilisation among patients with inflammatory arthritis: a population-based study

    Cohort studyRA

  24. Ann Rheum Dis

    Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls

    Research articleAcross diseases

  25. Ann Rheum Dis

    2021 EULAR points to consider to support people with rheumatic and musculoskeletal diseases to participate in healthy and sustainable paid work

    Guideline or statementAcross diseases

  26. Ann Rheum Dis

    After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries

    Cohort studyRA

  27. Ann Rheum Dis

    Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study

    Randomized controlled trialSpondyloarthritis & PsA

  28. Ann Rheum Dis

    3D genome alterations in T cells associated with disease activity of systemic lupus erythematosus

    Mechanistic studyLupus & APS

  29. Ann Rheum Dis

    Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies

    Cross-sectional studyMyositis

  30. Ann Rheum Dis

    Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission

    Secondary analysisVasculitis & PMR

  31. Ann Rheum Dis

    Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial

    Randomized controlled trialPediatric

  32. Ann Rheum Dis

    Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update

    Guideline or statementAcross diseases

  33. Ann Rheum Dis

    EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021

    Guideline or statementPediatric

  34. Ann Rheum Dis

    Instrument selection for the ASAS core outcome set for axial spondyloarthritis

    Guideline or statementSpondyloarthritis & PsA

  35. Ann Rheum Dis

    EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases

    Guideline or statementAcross diseases

  36. Ann Rheum Dis

    2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases

    Guideline or statementAcross diseases

All 596 Briefs in ExploreShowing Briefs 561–596 of 596, newest first